Overview

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Adrenal Cortex Hormones
lebrikizumab